Information  X 
Enter a valid email address

Uniphar PLC (UPR)

  Print   

Wednesday 11 May, 2022

Uniphar PLC

Result of AGM

RNS Number : 1573L
Uniphar PLC
11 May 2022
 

AGM Results

 

Dublin, London | 11 May 2022

 

 

Uniphar plc is pleased to announce that at the Annual General Meeting held at 11.00 a.m. today, 11 May 2022, each of the resolutions set out in the Notice of Annual General Meeting circulated to shareholders and made available on the Company's website, www.uniphar.ie , were duly passed without amendment.

 

Details of votes cast are set out below:

 

 

RESOLUTION

TOTAL

FOR

%

AGAINST

%

ABSTAIN

1

Financial Statements and Reports

139,441,694

139,441,694

100

0

0.00

147,705

2

Final Dividend of €2.9m

139,589,399

139,589,399

100

0

0.00

0

3(a)

Re-elect Ger Rabbette

139,589,399

135,469,357

97.05

4,120,042

2.95

0

3(b)

Re-elect Tim Dolphin

139,589,399

138,606,558

99.30

982,841

0.70

0

3(c)

Re-elect Paul Hogan

139,589,399

130,828,345

93.72

8,761,054

6.28

0

3(d)

Re-elect Sue Webb

139,589,399

135,343,699

96.96

4,245,700

3.04

0

3(e)

Re-elect Jeff Berkowitz *

139,589,399

110,242,453

78.98

29,346,946

21.02

0

3(f)

Re-elect Jim Gaul

139,589,399

132,497,099

94.92

7,092,300

5.08

0

3(g)

Re-elect Liz Hoctor

139,589,399

135,027,189

96.73

4,562,210

3.27

0

3(h)

Re-elect Maurice Pratt

139,589,399

131,537,248

94.23

8,052,151

5.77

0

4

Remuneration of Auditors

85,749,400

74,945,801

87.40

10,803,599

12.60

53,839,999

5

Allot relevant securities

139,589,399

134,987,663

96.70

4,601,736

3.30

0

6

Disapplication of pre-emption rights in specified circumstances

139,589,399

139,589,399

100

0

0

0

7

Disapplication of pre-emption rights in additional circumstances

139,589,399

139,589,399

100

0

0

 

0

8

Authorise market purchases of the Company's Ordinary Shares

138,858,398

138,858,398

100

0

0

731,001

9

Re-issuance of Treasury Shares

139,589,399

139,589,399

100

0

0

0

10

Amendment of the Company's Articles of Association to provide for annual retirement of all Directors

139,589,399

139,589,399

100

0

0

0

 

 

 

*The Board notes that Resolution 3(e) passed with a majority of less than 80% (receiving votes in favour of 78.98%). In accordance with provision 4 of the UK Corporate Governance Code (the "Code"), the Board confirms that it will engage with shareholders to understand and discuss the reasons behind the proxies received against this resolution. An update on the views received from shareholders and actions taken will be provided within six months of the AGM, in accordance with the Code.

 

 

--- ENDS ---

 

 

 

 

For further details contact:

 

Uniphar

+353 (0) 1 428 7777



Seamus Egan


Head of Corporate Development and IR

[email protected]



Davy

+353 (0) 1 679 6363

(Joint Corporate Broker, Nominated Adviser and Euronext

Growth Adviser)




Barry Murphy


Niall Gilchrist


Lauren O'Sullivan




RBC Capital Markets (Joint Corporate Broker)

+44 (0) 20 7653 4000



Jonathan Hardy


Jamil Miah






Stifel Nicolaus Europe Limited (Joint Corporate Broker)

 

+44 (0) 20 7710 7600

Matt Blawat


Ben Maddison


Francis North




Q4 PR

+353 (0) 1 475 1444 or

(Public Relations Adviser to Uniphar)

+353 87 235 6461



Iarla Mongey







 

 

 

 

About Uniphar plc

 

Headquartered in Dublin, Ireland, the Uniphar Group is an international diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions - Commercial & Clinical, Product Access and Supply Chain & Retail. The Group is active in Ireland, the UK, the Benelux, the Nordics, Germany, and the US.

 

The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.

 

Commercial & Clinical

In Commercial & Clinical, the Group provides outsourced sales, marketing & distribution solutions to multinational pharmaceutical and medical device manufacturers. Active in Ireland, the UK, the Benelux, the Nordics, Germany and the US, the Group is growing with its clients to provide pan-European solutions, with a bespoke offering in the US. Uniphar has built fully integrated digitally enabled customer centric solutions that are supported by our highly experienced and clinically trained teams, leveraging our digital technology and insights which allows us to deliver consistently exceptional outcomes for our clients.

 

Product Access

In Product Access, the Group is growing two distinct service offerings: 1) "On Demand", which are pharmacy led solutions for sourcing and supplying unlicensed medicines to meet the needs of both retail and hospital pharmacists; and 2) "Exclusive Access", which are manufacturer led solutions for controlling the release of speciality medicines for specifically approved patient populations in agreed markets. The Group currently delivers product access solutions on a global basis.

 

Supply Chain & Retail

Uniphar is an established market leader in Ireland with c. 53% market share in the wholesale/hospital market, supported by a network of 378 owned, franchised and symbol group pharmacies. The business supports the diverse customer base through the provision of strong service levels coupled with innovative commercial initiatives. Supply Chain & Retail is an Irish only business for the Group, although the manufacturer relationships and infrastructure are also utilised for the benefit of Commercial & Clinical and Product Access.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFLFVSEIILLIF

a d v e r t i s e m e n t